RxDoctor Payments DataLook up a doctor →

Jon Poling, MD

Neurology · Athens, GANPI 1457303638

Payments from drug & device makers

$68,497in general payments, 2019–2025

Across 597 payments — averaging $114.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • AbbVie$19K
  • Eli Lilly$17K
  • Catalyst Pharmaceuticals, Inc.$4K
  • Argenx US, Inc.$2K
  • Banner Life Sciences, LLC$971
  • plus $6K from 50 others
$8,991in research payments, 2019–2025

Across 1 payment — averaging $8991.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)42$20,161
AbbVie(2 entities)215$19,253
Eli Lilly3$16,821
Catalyst Pharmaceuticals, Inc.6$3,612
Argenx US, Inc.7$1,630
Banner Life Sciences, LLC5$971
EMD Serono, Inc.58$836
Sunovion Pharmaceuticals Inc.53$521
UCB, Inc.21$475
Novartis29$473
AstraZeneca(2 entities)10$336
TG Therapeutics, Inc.10$334
Pfizer26$277
GE HealthCare3$233
MDD US Operations, LLC7$221
Biogen8$200
Lundbeck LLC8$195
Neurocrine Biosciences, Inc.6$189
Johnson & Johnson(2 entities)3$170
Eisai Inc.5$138
Regeneron Healthcare Solutions, Inc.3$100
Acadia Pharmaceuticals Inc5$83
Kyowa Kirin, Inc.1$81
Octapharma USA, Inc.4$80
Lilly USA, LLC5$74
Harmony Biosciences LLC3$73
SK Life Science, Inc.3$72
Takeda Pharmaceuticals U.S.A., Inc.4$72
Ipsen Biopharmaceuticals, Inc3$63
Genentech USA, Inc.3$62
Jazz Pharmaceuticals Inc.3$59
Amneal Pharmaceuticals LLC3$52
Immedica Pharma US, Inc.2$48
Adamas Pharmaceuticals, Inc.3$47
Biohaven Pharmaceuticals, Inc.3$40
Sanofi2$38
Springworks Therapeutics, Inc.1$33
Supernus Pharmaceuticals, Inc.2$31
Mallinckrodt Hospital Products Inc.2$31
Sumitomo Pharma America, Inc.1$24
Otsuka America Pharmaceutical, Inc.1$23
Amylyx Pharmaceuticals, Inc.1$22
Averitas Pharma Inc.1$21
ANI Pharmaceuticals, Inc.1$20
Kedrion Biopharma, Inc.1$20
E.r. Squibb & Sons, L.L.C.1$19
Scilex Pharmaceuticals Inc.1$19
Cycle Pharmaceuticals Inc1$18
Bristol Myers Squibb1$18
Vanda Pharmaceuticals Inc.1$18
Greenwich Biosciences, Inc.1$18
Biohaven Pharmaceutical Holding Company Ltd.1$15
Neurelis, Inc.1$15
Merz Pharmaceuticals, LLC1$14
Impel Pharmaceuticals Inc.1$14
Resmed Corp1$14

How this compares

$68,497 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia →

Medicare billing

Part B allowed, 2024
$1,331,118
Medicare patients
906
Services billed
78,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Athens

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →